Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 7/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771570 | 0.93 | MAPK8 (0.50) | PTK2MAPK8MAPK9EGFRJAK3 | |
| SCHEMBL4825515 | 0.91 | MAPK8 (0.48) | PTK2MAPK8MAPK9EGFRJAK3 | |
| SCHEMBL4773873 | 0.90 | MAPK8 (0.51) | PTK2MAPK8MAPK9EGFRJAK3 | |
| SCHEMBL4767520 | 0.87 | MAPK8 (0.54) | PTK2MAPK8MAPK9EGFRJAK3 | |
| SCHEMBL4771563 | 0.85 | EGFR (0.49) | MAPK8MAPK9EGFRJAK3BTK | |
| SCHEMBL4770474 | 0.83 | EGFR (0.47) | PTK2EGFRJAK3BTKAURKA | |
| SCHEMBL4771780 | 0.82 | EGFR (0.46) | PTK2EGFRJAK3BTKAURKA | |
| SCHEMBL4775725 | 0.81 | CDK2 (0.49) | PTK2MAPK8MAPK9JAK3BTK | |
| SCHEMBL4770594 | 0.81 | MAPK9 (0.51) | PTK2MAPK8MAPK9EGFRJAK3 | |
| SCHEMBL4769925 | 0.80 | AURKA (0.48) | PTK2MAPK8MAPK9EGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098332-B2 | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | claimed |
| EP-1581531-A1 | PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056822-A1 | PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-20040122029-A1 | Novel dihydropyridinone compounds | LIU JIN-JUN (US) | 2004-06-24 | — | — | US | claimed |
| EP-1581531-B1 | PYRIDINO¬2,3-D PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-7098332-B2 | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1581531-A1 | PYRIDINO[2,3-D]PYRIMIDINE DERIVATIVES AS SELECTIIVE KDR AND FGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056822-A1 | PYRIDINO `2, 3-D! PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| US-20040122029-A1 | Novel dihydropyridinone compounds | LIU JIN-JUN (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122029-A1 | Novel dihydropyridinone compounds | FGFR1, FGFR3, FGFR4 | PTK2 41/4885MAPK8 477/4885MAPK9 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.